ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)
Results from this trial for sarcomatoid renal cell carcinoma (RCC) [...]
Immune signature for papillary RCC predicts outcomes
A recent study published in Cancer Medicine has identified immune-related [...]
Potential predictive biomarker of response to VEGF treatment in metastatic kidney cancer
A recent study published on PLOS/ONEÂ has identified three genetic mutations/alterations [...]
Nivolumab plus ipilimumab combination shows survival benefit for patients with untreated kidney cancer at 30 months
Further survival data has been released from the phase 3 [...]
First-line cabozantinib declined for a second time for use within NHS Scotland
Cabozantinib has been declined for a second time by the [...]
Four distinct subgroups of clear cell renal cancer identified
Using gene profiling, a recent study published in Cancer Discovery [...]
Incidence of some obesity-related cancers in increasing in younger people
A recent study, published in The Lancet Public Health, has [...]
Potential kidney cancer test in development
A Swedish biotechnology company, Elypta, has recently been awarded an [...]
Second-line treatment with axitinib in favourable risk patients
Results from a phase 2 study to assess the activity [...]
Real world safety and efficacy of nivolumab for kidney cancer
A recent study reports the real-world safety and efficacy of [...]
